Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0

作者：

Hungria, Vania T. M. ^{[1
]}

Weisel, Katja ^{[2
]}

Radinoff, Atanas ^{[3
]}

Delimpasi, Sosana ^{[4
]}

Mikala, Gabor ^{[5
]}

Masszi, Tamas ^{[6
]}

Li, Jian ^{[7
]}

Capra, Marcelo ^{[8
]}

Maiolino, Angelo ^{[9
]}

Pappa, Vasiliki ^{[10
]}

Chraniuk, Dominik ^{[11
]}

Osipov, Iurii ^{[12
]}

Leleu, Xavier ^{[13
]}

Low, Michael ^{[14
]}

Kouri, Fotini ^{[15
]}

Liboon, John ^{[16
]}

Brawley, Chris ^{[17
]}

Lewis, Eric ^{[18
]}

Tubel, Gabriela

Li, Mary ^{[18
]}

McKeown, Astrid

Roy-Ghanta, Sumita ^{[18
]}

Opalinska, Joanna ^{[18
]}

Dimopoulos, Meletios ^{[19
]}

机构：

[1] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Univ Hosp St Ivan Rilski EAD, Dept Clin Hematol, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] Natl Inst Haematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, South Pest Cent Hosp, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Hematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[9] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil

[10] Univ Gen Hosp Attikon, Hematol Unit, Dept Internal Med & Res Unit 2, Athens, Greece

[11] Wojewodzki Szpital Zespolony, Dept Hematol, Torun, Poland

[12] VA Almazov Natl Med Res Ctr, St Petersburg, Russia

[13] CHU Poitiers, PRC, Hematol, Poitiers, France

[14] Clayton Univ, Monash Univ, Monash Hlth, Monash Haematol, Clayton, Vic, Australia

[15] GSK, Stevenage, Herts, England

[16] GSK, San Diego, CA USA

[17] GSK, London, England

[18] GSK, Upper Providence, PA USA

[19] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-395

引用

页码：S261 / S262

页数：2

共 50 条

[1] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
Hungria, Vania
Weisel, Katja
Currie, Brooke
Perera, Sue
Sule, Neal
He, Wei
Davy, Katherine
McKeown, Astrid
Sapra, Sandhya
Nelsen, Linda
Li, Mary
Barale, Sophie
Boyle, Julia
McPoyle, Kaytlyn
Dimopoulos, Meletios Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
[2] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
Trudel, Suzanne
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Quach, Hang
Vorobyev, Vladimir I.
Cavo, Michele
Suzuki, Kazuhito
Robak, Pawel
Morris, Kristin
Phillips-Jones, Amy
Zhou, Xiaoou Linnette
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Mateos, Maria-Victoria
Dimopoulos, Meletios Athanasios
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
[3] Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Trudel, Suzanne
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Vorobyev, Vladimir
Hang Quach
Spicka, Ivan
Radocha, Jakub
Robak, Pawel
Kim, Kihyun
Cavo, Michele
Suzuki, Kazuhito
Morris, Kristin
Pompilus, Farrah
Wilkes, Jodie
Philips-Jones, Amy
Zhou, Xiaoou
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Mateos Manteca, Maria-Victoria
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S39 - S40
[4] DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
Weisel, K.
Dimopoulos, M. A.
Hungria, V. T. M.
Radino, A.
Delimpasi, S.
Mikala, G.
Masszi, T.
Li, J.
Capra, M.
Matsumoto, M.
Sule, N.
Li, M.
McKeown, A.
He, W.
Bright, S.
Currie, B.
Boyle, J.
Opalinska, J.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 233 - 234
[5] Patient (pt)-reported outcomes in pts with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin (belamaf) vs pomalidomide/low dose dexamethasone (Pd) in the phase III, open-label, randomized, multicenter DREAMM-3 study
Weisel, K.
Hungria, V.
Currie, B.
Perera, S.
Sule, N.
He, W.
McKeown, A.
Sapra, S.
Li, M.
Barale, S.
Boyle, J.
McPoyle, K.
Dimopoulos, M. A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 180 - 180
[6] A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)
Weisel, Katja
Hungria, Vania T. M.
Radinoff, Atanas
Delimpasi, Sosana
Gabor, Mikala
Masszi, Tamas
Li, Jian
Capra, Marcelo
Matsumoto, Morio
Sule, Neal
Li, Mary
McKeown, Astrid
He, Wei
Bright, Shelley
Currie, Brooke
Boyle, Julia
Opalinska, Joanna
Dimopoulos, Meletios Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S505
[7] Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Dimopoulos, Meletios Athanasios
Hungria, Vania T. M.
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Matsumoto, Morio
Sule, Neal
Li, Mary
McKeown, Astrid
He, Wei
Bright, Shelley
Currie, Brooke
Perera, Sue
Boyle, Julia
Roy-Ghanta, Sumita
Opalinska, Joanna
Weisel, Katja
LANCET HAEMATOLOGY, 2023, 10 (10): : E801 - E812
[8] Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) plus bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Mateos, Maria-Victoria
Robak, Pawel
Hus, Marek
Xia, Zhongjun
Zherebtsova, Vera
Ward, Christopher
Ho, P. Joy
Hajek, Roman
Kim, Kihyun
Dimopoulos, Meletios A.
Cerchione, Claudio
Riccio, Antonio
McKeown, Astrid
Rogers, Rachel
Baig, Hena
Eccersley, Lydia
Roy-Ghanta, Sumita
Opalinska, Joanna
Hungria, Vania
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (36_SUPPL) : 439572 - 439572
[9] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Trudel, Suzanne
Davis, Randy
Lewis, Nicole M.
Bakshi, Kalpana K.
Chopra, Bikramjit
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Eliason, Laurie
Kremer, Brandon E.
Stowell, Delia
Gupta, Ira
Wu, Frank S.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
[10] A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
Weisel, Katja
Hungria, Vania T. M.
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Matsumoto, Morio
Sule, Neal
Li, Mary
McKeown, Astrid
He, Wei
Bright, Shelley
Currie, Brooke
Boyle, Julia
Opalinska, Joanna
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →